There were 809 press releases posted in the last 24 hours and 403,570 in the last 365 days.

Fraudulent Activity and Unlawful Sales of Unapproved and Misbranded Drug Products | COVID-19

FDA considers the sale and promotion of fraudulent COVID-19 products to be a threat to the public health. We have a surveillance program that routinely monitors online sources for health fraud products, especially during a significant public health issue such as this one. 

FDA is exercising its authority to protect consumers from firms selling unapproved products and making false or misleading claims, including, by pursuing warning letters, seizures, or injunctions against products and firms or individuals that violate the law. We understand the concern about the spread of COVID-19 and urge you to talk to your health care providers, as well as follow advice from other federal agencies about how to prevent the spread of this illness.


Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.